Effects of Bailing capsules combined with levothyroxine sodium on autoimmune thyroiditis

To explore the clinical effects and adverse reactions of Bailing capsules combined with levothyroxine sodium for autoimmune thyroiditis, 70 patients with autoimmune thyroiditis were retrospectively enrolled and divided into the Bailing treatment group and the control, both consisting of 35 patients. The control group was treated with levothyroxine sodium alone, and the treatment group with Bailing capsules combined with levothyroxine sodium. The clinical efficacy, thyroid function indicators, antibodies and inflammatory indicators, and adverse drug reactions were analyzed. The total treatment effective rate was significantly (P = .04) higher in the treatment (94.29%) than in the control group (77.14%). After treatment, the levels of free triiodothyronine (8.69 ± 1.02 vs 6.70 ± 1.12 pmol/L) and free thyroxine (FT4) (20.05 ± 2.33 vs 13.00 ± 2.41 pmol/L) were significantly (P < .001) higher in the treatment group than those in the control group, the levels of thyroid peroxidase antibody (TPOAb) (298.70 ± 65.08 vs 735.15 ± 93.39 U/mL) and thyroglobulin antibodies (TgAb) (93.37 ± 21.10 vs 194.20 ± 37.48 U/mL) in the treatment group were significantly (P < .05) lower than those in the control group, and the interleukin-6 (IL-6) (82.83 ± 3.15 vs 97.17 ± 2.27 ng/L) and interleukin-17 (6.02 ± 0.67 vs 6.89 ± 0.72 ng/L) indicators in the treatment group were significantly (P < .05) lower than those in the control group. No significant (P = .393) difference was found in the adverse drug reaction. In conclusion, Bailing capsules combined with levothyroxine sodium are effective and safe for autoimmune thyroiditis, with good control of disease progression, improvement of thyroid function, reduction of thyroid function-related antibody level, and inhibition of inflammation.